利拉鲁肽治疗非糖尿病肥胖和超重的效果(1)
[摘要]目的 探讨利拉鲁肽治疗非糖尿病肥胖和超重的效果。方法 选取2017年3月～2018年4月在本院就诊的非糖尿病肥胖和超重患者53例为研究对象，随机分为治疗组(27例)和对照组(26例)。对照组患者单纯给予适当饮食控制及适量运动，治疗组患者在对照组基础上，同时应用利拉鲁肽注射液治疗，所有患者均連续治疗12 周。观察两组患者治疗前和治疗后的体重指数(BMI)、体重、血脂血糖情况、糖化血红蛋白，并进行比较。结果 治疗组治疗后的BMI、体重、三酰甘油、低密度脂蛋白均低于对照组，差异有统计学意义(P<0.01)。两组治疗后的空腹血糖以及糖化血红蛋白水平比较，差异无统计学意义(P>0.05)。所有患者均无因为不良反应情况而需要调整者，所有患者均无低血糖反应。结论 非糖尿病肥胖和超重患者应用利拉鲁肽治疗后，体重和BMI降低明显，未出现低血糖反应，不良反应轻，值得研究应用推广。
[关键词]非糖尿病;肥胖;超重;利拉鲁肽
[中图分类号] R723.14 [文献标识码] A [文章编号] 1674-4721(2019)10(b)-0047-05
[Abstract] Objective To explore the effect of Liraglutide treating non-diabetic obesity and overweight. Methods From March 2017 to April 2018， fifty-three patients with non-diabetic obesity and overweight treated in our hospital were selected as study objects and they were randomly divided into the treatment group (27 cases) and control group (26 cases). Patients in the control group were given appropriate diet control and moderate exercise， while patients in the treatment group were treated by Liraglutide Injection on the basis of the control group. All patients were treated for 12 weeks. The body mass index (BMI)， body weight， blood lipid， blood sugar and glycosylated hemoglobin of the two groups were observed before and after treatment， and compared. Results BMI， body weight， triglyceride and low density lipoprotein in the treatment group after treatment were lower than those in the control group， and the differences were statistically significant (P<0.01). There were no significant differences in fasting blood glucose and glycosylated hemoglobin levels between the two groups after treatment (P>0.05). There was no need to adjust for adverse reactions in all patients， and no hypoglycemic reaction occurred in all patients. Conclusion After the treatment of non-diabetic obesity and overweight patients with Liraglutide， the body weight and BMI decrease significantly， there is no hypoglycemic reaction， and the adverse reactions are mild， which deserves to be studied， applied and popularized.
[Key words] Non-diabetes mellitus; Obesity; Overweight; Liraglutide
世界卫生组织估计2015年全球成年人口中有约23亿人超重，有7亿人口达到肥胖水平，中国居民营养与慢性病状况报告2015指出全国18岁及以上成人在2012年超重率就已经达到了30.1%，肥胖率为11.9%，比2002年均有较大上升[1]。肥胖是高血糖、高血脂、冠状动脉粥样硬化、高血压、非酒精性脂肪性肝病、生殖系统疾病、阻塞性睡眠呼吸暂停低通气综合征和肥胖低通气综合征等的危险因素，体重减轻可减少相关疾病的发生和发展。单纯采用严格的饮食控制及运动控制体重对很多患者来说难以坚持，很多患者因此减重失败。胰升血糖素样肽-1(GLP-1)受体激动剂被广泛应用于2型糖尿病合并肥胖的患者并取得了较好的疗效，欧美对其治疗非糖尿病肥胖也进行了一些研究并取得了好的疗效[2]，国内关于治疗中国非糖尿病肥胖患者的研究报道较少，是否能适用于中国患者，笔者就GLP-1受体激动剂——利拉鲁肽对非糖尿病肥胖和超重的治疗问题进行探索，现报道如下。, 百拇医药(沈亚东 吴继峰)
[关键词]非糖尿病;肥胖;超重;利拉鲁肽
[中图分类号] R723.14 [文献标识码] A [文章编号] 1674-4721(2019)10(b)-0047-05
[Abstract] Objective To explore the effect of Liraglutide treating non-diabetic obesity and overweight. Methods From March 2017 to April 2018， fifty-three patients with non-diabetic obesity and overweight treated in our hospital were selected as study objects and they were randomly divided into the treatment group (27 cases) and control group (26 cases). Patients in the control group were given appropriate diet control and moderate exercise， while patients in the treatment group were treated by Liraglutide Injection on the basis of the control group. All patients were treated for 12 weeks. The body mass index (BMI)， body weight， blood lipid， blood sugar and glycosylated hemoglobin of the two groups were observed before and after treatment， and compared. Results BMI， body weight， triglyceride and low density lipoprotein in the treatment group after treatment were lower than those in the control group， and the differences were statistically significant (P<0.01). There were no significant differences in fasting blood glucose and glycosylated hemoglobin levels between the two groups after treatment (P>0.05). There was no need to adjust for adverse reactions in all patients， and no hypoglycemic reaction occurred in all patients. Conclusion After the treatment of non-diabetic obesity and overweight patients with Liraglutide， the body weight and BMI decrease significantly， there is no hypoglycemic reaction， and the adverse reactions are mild， which deserves to be studied， applied and popularized.
[Key words] Non-diabetes mellitus; Obesity; Overweight; Liraglutide
世界卫生组织估计2015年全球成年人口中有约23亿人超重，有7亿人口达到肥胖水平，中国居民营养与慢性病状况报告2015指出全国18岁及以上成人在2012年超重率就已经达到了30.1%，肥胖率为11.9%，比2002年均有较大上升[1]。肥胖是高血糖、高血脂、冠状动脉粥样硬化、高血压、非酒精性脂肪性肝病、生殖系统疾病、阻塞性睡眠呼吸暂停低通气综合征和肥胖低通气综合征等的危险因素，体重减轻可减少相关疾病的发生和发展。单纯采用严格的饮食控制及运动控制体重对很多患者来说难以坚持，很多患者因此减重失败。胰升血糖素样肽-1(GLP-1)受体激动剂被广泛应用于2型糖尿病合并肥胖的患者并取得了较好的疗效，欧美对其治疗非糖尿病肥胖也进行了一些研究并取得了好的疗效[2]，国内关于治疗中国非糖尿病肥胖患者的研究报道较少，是否能适用于中国患者，笔者就GLP-1受体激动剂——利拉鲁肽对非糖尿病肥胖和超重的治疗问题进行探索，现报道如下。, 百拇医药(沈亚东 吴继峰)